Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 6/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 3/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL140027 | 0.89 | CYP2C8 (0.72) | CYP2C8KCNH2CYP3A4NR1I2IDO1 | |
| SCHEMBL12330699 | 0.83 | CYP2C8 (0.62) | CYP2C8KCNH2CYP3A4NR1I2IDO1 | |
| SCHEMBL19401316 | 0.79 | CYP2C8 (0.68) | CYP2C8KCNH2CYP3A4NR1I2IDO1 | |
| SCHEMBL19401443 | 0.79 | CYP2C8 (0.67) | CYP2C8KCNH2CYP3A4NR1I2IDO1 | |
| SCHEMBL18751636 | 0.76 | CYP2C8 (0.59) | CYP2C8KCNH2CYP3A4NR1I2IDO1 | |
| SCHEMBL12330955 | 0.76 | CYP2C8 (0.59) | CYP2C8KCNH2CYP3A4NR1I2IDO1 | |
| SCHEMBL141259 | 0.75 | CYP2C8 (0.72) | CYP2C8KCNH2CYP3A4NR1I2IDO1 | |
| SCHEMBL143635 | 0.75 | CYP2C8 (0.72) | CYP2C8KCNH2CYP3A4NR1I2IDO1 | |
| SCHEMBL121622 | 0.75 | CYP2C8 (0.79) | CYP2C8KCNH2CYP3A4NR1I2MAPK14 | |
| SCHEMBL146279 | 0.74 | CYP2C8 (0.76) | CYP2C8KCNH2CYP3A4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545051-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2017-04-19 | — | — | EP | disclosed |